Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft

Slavčev, Antonij; Brožová, Jitka; Slatinska, Janka; Sekerkova, Zuzana; Honsová, Eva; Skibová, J; Striz, Ilja; Viklický, Ondřej

doi:10.1007/s00005-016-0428-4

Cited by 10 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike the results showed by different groups where no differences were found in BAFF levels between kidney transplant recipients and controls [31] indicating that this molecule is not a prognostic marker for allograft dysfunction, or that no correlation exists between BAFF and the production of DSA before and after transplantation [32], in the present study we observed that patients with AbMR presented higher levels of BAFF before transplantation, being also elevated BAFF serum levels in those patients with anti-HLA antibodies and DSA. These results are in a relationship published by other authors showing that BAFF is associated with allograft survival [37], acute antibody-mediated rejection as well as the presence of DSA [28,29,38].…”

Section: Discussioncontrasting

confidence: 99%

“…On the one hand, some authors indicate that BAFF reflects the immunological risk profile of patients after kidney transplantation (KT), considering that pretransplant BAFF levels are associated with pretransplant sensitization and are useful in predicting allograft rejection [23][24][25]; BAFF expression correlates with pretransplant panel reactive antibody (PRA), indicating that BAFF may be involved in the development of graft loss [26]; elevated levels of BAFF are associated with antibody-mediated clinical damage in KT [27], and with an increased risk of acute AbMR [28][29][30]. On the other hand, there are authors that affirm that BAFF is not a prognostic marker for allograft dysfunction or survival in KT patients because BAFF serum levels are not related to anti-HLA sensitization [31]; significantly lower levels of BAFF are found in patients experiencing AbMR [32]; or high BAFF is not associated with the graft outcome in KT with rituximab induction [33]. A meta-analysis published recently evaluated the predictive value of serum BAFF for AbMR, indicating that the incidence of AbMR was significantly higher in patients with high levels of BAFF [34].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection

Irure‐Ventura

Segundo

Rodrigo

et al. 2020

IJMS

View full text Add to dashboard Cite

Antibody-mediated rejection (AbMR) is one of the leading causes of graft loss in kidney transplantation and B cells play an important role in the development of it. A B-cell activating factor (BAFF) is a cytokine involved in B cell ontogeny. Here, we analyzed whether B cell maturation and the effect of B cell soluble factors, such as BAFF could be involved in AbMR. Serum BAFF levels and B and T cell subpopulations were analyzed 109 kidney transplant patients before transplantation and at 6 and 12 months after kidney transplantation. Pretransplant serum BAFF levels as well as memory B cell subpopulations were significantly higher in those patients who suffered clinical AbMR during the first 12 months after kidney transplantation. Similar results were observed in the prospective analysis of patients with subclinical antibody-mediated rejection detected in the surveillance biopsy performed at 12 months after kidney transplantation. A multivariate analysis confirmed the independent role of BAFF in the development of AbMR, irrespective of other classical variables. Pretransplant serum BAFF levels could be an important non-invasive biomarker for the prediction of the development of AbMR and posttransplant increased serum BAFF levels contribute to AbMR.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection

Irure‐Ventura

Segundo

Rodrigo

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In contrast, the risk of AMR was not observed in recipients without DSA (9). Slavcev et al claimed no correlation was found between BAFF and the production of donor-specific antibodies before and after transplantation, and the serum concentrations of BAFF in patients with AMR and kidney recipients without rejection did not significantly differ (12). In addition to these controversies, the clinical significance of BAFF in predicting rejection is not well-understood.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies demonstrated that BAFF are associated with an increased risk of subsequent antibody-mediated acute rejection (9–11), while there are objections. Slavcev et al demonstrated that the pretransplant serum concentrations of BAFF in patients with antibody-mediated acute rejection and kidney recipients without rejection did not significantly differ (12). In addition, studies have focused on the relationship between BAFF and AMR, and the role in cell-mediated rejection (CMR) is still unclear.…”

Section: Introductionmentioning

confidence: 99%

B-Cell Activating Factor Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-Up Study

et al. 2019

View full text Add to dashboard Cite

B cell activating factor (BAFF) belonging to TNF family is a cytokine that enhances B-cell proliferation and differentiation. Recently, It has been suggested that BAFF might be a potential therapeutic target for treating autoimmune disease. However, the relationship between BAFF and allograft rejection is controversial, and the clinical significance of BAFF in predicting allograft rejection need to be further explored. We conducted 6-month follow-up study to confirm the hypothesis that BAFF might be a risk factor for predicting acute rejection in kidney transplant recipients. At the end of the study, a total of 155 kidney transplant recipients were recruited from October 2015 to October 2017, and classified into acute rejection group ( n = 34) and stable renal function group ( n = 121) according to their clinical course. We demonstrate that the serum BAFF levels when acute rejection occurred was significantly higher than that in the stable renal function group (2426.19 ± 892.19 vs. 988.17 ± 485.63 pg/mL, P < 0.05). BAFF expression was significantly enhanced in the membrane and cytoplasm of renal tubule epithelial cells in the transplant kidney tissue with acute rejection, and a positive correlation between BAFF and C4d expression was also observed ( r = 0.880, P = 0.001). ROC analyses highlight the superiority of serum BAFF level before transplant over those on other post-transplant days in prediction of acute rejection episodes. The sensitivity, specificity and AUC (area under curve) were 83.3, 89.5, and 0.886%, respectively. Kaplan-Meier survival analysis showed that recipients with higher pretransplant BAFF levels had higher acute rejection incidence ( P = 0.003). In conclusion, we have identified that BAFF levels are associated with the acute rejection and could be a promising biomarker to predict kidney transplant rejection risks.

show abstract

“…In literature, there are different observations regarding the relationship between BAFF and the development of DSA. In their work, Slavcec found no correlation between increased BAFF values and the increased occurrence of de novo donor-specific antibodies [ 18 ]. In contrast, in the work of Thibault et al, de novo DSA can be detected in transplant patients with high BAFF levels and unstable kidney function [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation

et al. 2021

View full text Add to dashboard Cite

The B cell activating factor BAFF has gained importance in the context of kidney transplantation due to its role in B cell survival. Studies have shown that BAFF correlates with an increased incidence of antibody-mediated rejection and the development of donor-specific antibodies. In this study, we analyzed a defined cohort of kidney transplant recipients who were treated with standardized immunosuppressive regimens according to their immunological risk profile. The aim was to add BAFF as an awareness marker in the course after transplantation to consider patient’s individual immunological risk profile. Included patients were transplanted between 2016 and 2018. Baseline data, graft function, the occurrence of rejection episodes, signs of microvascular infiltration, and DSA kinetics were recorded over 3 years. BAFF levels were determined 14 d, 3 and 12 months post transplantation. Although no difference in graft function could be observed, medium-risk patients showed a clear dynamic in their BAFF levels with low levels shortly after transplantation and an increase in values of 123% over the course of 1 year. Patients with high BAFF values were more susceptible to rejection, especially antibody-mediated rejection and displayed intensified microvascular inflammation; the combination of high BAFF + DSA puts patients at risk. The changing BAFF kinetics of the medium risk group as well as the increased occurrence of rejections at high BAFF values enables BAFF to be seen as an awareness factor. To compensate the changing immunological risk, a switch from a weaker induction therapy to an intensified maintenance therapy is required.

show abstract

Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft

Cited by 10 publications

References 19 publications

High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection

High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection

B-Cell Activating Factor Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-Up Study

B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation

Contact Info

Product

Resources

About